Abdi İbrahim Pharmaceuticals

Contact Person

Name: Köksal Ülgen
Position: President, International Markets
Phone: +90 212 366 86 87
Email: koksal.ulgen@abdiibrahim.com.tr
Address: Resitpasa Mah. Eski Buyukdere Cad. No:4 34467 Maslak, Sariyer-Istanbul/Turkey
Website: http://www.abdiibrahim.com.tr

Brief Description of the Company: Turkish pharmaceutical industry leader Abdi İbrahim’s journey of healing began in a small pharmacy store in 1912 established by the Pharmacist Abdi İbrahim Bey in Küçükmustafapaşa, Istanbul. Today, in addition to its partnerships with more than 30 licensing firms across the globe, Abdi İbrahim develops its products and boasts the largest portfolio in the industry, with 250 brands and over 500 products.

With its powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has held a leading position in the Turkish pharmaceutical industry since 2002. Today, Abdi İbrahim has subsidiaries operating in 19 countries outside Türkiye — Albania, Algeria, Azerbaijan, Bosnia and Herzegovina, Georgia, Germany, Iraq, Italy, Kazakhstan, Kosovo, Kyrgyzstan, Morocco, North Macedonia, Saudi Arabia, Serbia, Tunisia, UAE, UK and Uzbekistan — exports to more than 70 countries from the European Union to Canada, North Africa to Asia and the Middle East and generates the highest employment rate in the Turkish pharmaceutical industry with 6,000 qualified employees. The company also stands out with the industry's largest marketing and sales team. Abdi İbrahim R&D Center is the first accredited pharmaceutical R&D center in Türkiye. The technology and architecture of the facility is a testament to Abdi İbrahim’s focus on R&D as an essential tool for healing the future.

The R&D Center is situated within Abdi İbrahim’s production complex in Esenyurt, Istanbul, which also houses the company’s Chemical Products Production Facility, Türkiye’s largest biotechnological manufacturing facility AbdiBio, Hormone Production Facility, Sterile Ophthalmology & Sterile Inhalation Production Facility, and Chemical, Oncology, and Sterile Supplementary Production Facility. Abdi İbrahim also has R&D centers and production facilities in Kazakhstan and Algeria.

In 2010, Abdi Farma was established with marketing authorisation for all Abdi İbrahim products in European markets. Abdi İbrahim's innovative products are available in Portugal, Germany, Italy, the United Kingdom, France, the Netherlands, Croatia, the Czech Republic and Spain.

In 2012, Abdi İbrahim Otsuka was established with a 50% partnership with Otsuka Pharmaceutical, one of Japan's most established pharmaceutical companies. Abdi İbrahim Otsuka offers innovative approaches and treatment solutions, which are firsts and often the only ones in their respective field, for rare diseases such as CNS disorders, cardiovascular system diseases and polycystic kidney disease to improve the lives of patients and their relatives.

Abdi İbrahim was part of the Swiss joint venture that acquired OM Pharma, an 88-year-old pharma company based in Switzerland, one of the leading countries in the pharmaceutical industry, in 2020. After the acquisition, Abdi İbrahim owned a 28.5 percent stake in OM Pharma. With this acquisition, Abdi İbrahim has become the sole foreign partner of the consortium that acquired OM Pharma, and the first and only Turkish pharmaceutical company to establish a strategic partnership with a European peer.

In 2024, the joint venture company ‘Abdi Cigalah Pharma’ was established with a 50 percent partnership with Cigalah Healthcare, the leading company in Saudi Arabia and the Gulf countries in the fields of pharmaceuticals and consumer health. The partnership covers the export of Abdi İbrahim's innovative products to other Gulf countries starting from the Saudi market. In its 100th anniversary year, Abdi İbrahim launched the campaign “Rational Use of Medicines”, which aims to raise public awareness and create long-term behavioural change on the issue of careless use of medicine, which is a significant concern for both public health and the national economy.

In 2015, Abdi İbrahim renovated the health museum in Dar al-Shifa, focusing on Ottoman medicine from the 15th to the 18th century, making the treasures of our medical history accessible to the public. With The Sultan Bayezid II Edirne Hospital Restoration Project, Abdi İbrahim received six national and international awards in the fields of communication and social responsibility. Abdi İbrahim has integrated sustainability into all of its business processes as befits its duty as a corporate citizen, its industry mission, and social priorities that call for a better world and a better future. Abdi İbrahim shapes all actions with an ESG (Environmental, Social, Governance) perspective, which offers the company the opportunity to measure its performance not only in terms of positive financial results but also in terms of its impact on society and the environment.

In 2010, Abdi İbrahim took a significant step by signing the United Nations Global Compact, allowing it to showcase its excellent standards in human rights, the environment and social responsibility. Abdi İbrahim also discloses its sustainability efforts with a Sustainability Report, which follows the Global Reporting Initiative (GRI) standards.

As part of the green transformation, Abdi İbrahim has taken numerous steps in the field of sustainability and continues to make improvements in all business processes for a better future, guided by sustainability initiatives such as the European Green Deal and the United Nations Sustainable Development Goals (SDGs), as well as materiality analyses and Organizational Life Cycle Analysis (O-LCA) within the organization.

Since 2020, Abdi İbrahim has been the first pharmaceutical company in Türkiye to power its facilities, namely the Esenyurt Production Complex and the Abdi İbrahim Tower, with 100 percent renewable energy. Having carried out significant efforts to reduce its carbon footprint, the company developed its strategy in 2023 and set its main targets for 2030, 2040 and 2050, focusing on creating long-term value. The company aims to become a carbon-neutral company in 2030 and to achieve net zero emissions in 2050.

Abdi İbrahim is the only Turkish pharmaceutical company to sign the Science Based Targets Initiative (SBTi) and have its carbon footprint reduction commitments approved by the organization. As another important step, Abdi İbrahim reports annually to the Carbon Disclosure Project (CDP) Climate Change Program. In 2023, Abdi İbrahim became the first and only Turkish pharmaceutical company to secure a place on the CDP Climate Change Program’s prestigious A List, marking a significant milestone on the international stage. Building on this achievement, the company’s unwavering commitment to sustainability was once again recognized in 2024, as it earned a spot on the Climate A List for the second consecutive year and received an A- rating in the Water Security Program — a testament to its leadership and impact in advancing environmental responsibility.

Abdi İbrahim also attaches great importance to water sustainability and became the first Turkish pharmaceutical company to sign the CEO Water Mandate, an initiative of the United Nations Global Compact.

Within the scope of the HEAL2050 sustainability strategy, Abdi İbrahim has implemented a social investment program consisting of 3 main topics: ‘Abdi İbrahim Foundation’, ‘Social Innovation in Health’, ‘Creating Science Awareness in Youth’.; In this direction;
• Abdi İbrahim Foundation: Focusing on Health, Education and Sports, Abdi İbrahim Foundation was established in 2021. Under the umbrella of the Foundation, the House of Kindness, Education Scholarship and Brave Strokes projects are carried out.
• Social Innovation in Health: The DOZ Program was launched in 2021 in cooperation with Impact Hub to support impact-oriented entrepreneurs who develop innovative health technologies solutions.
• Creating Science Awareness among Young People: In 2022, Explorers of the Future Program was launched in collaboration with the Bilim Virüsü learning initiative to empower visionary individuals, believe in science, are entrepreneurial and have 21st century competencies. The program aims to equip high school students aged 15-18 across Türkiye with scientific thinking habits and new generation competences.

Driven by its industry mission, social priorities, and role as a corporate citizen, Abdi İbrahim strives for a better world and future, which drives the company to focus on sustainability in all its business processes. As a company with one hundred percent domestic capital, it increases its effectiveness in international markets day by day and continues its activities uninterruptedly to be among the world's top 100 pharmaceutical companies in addition to its strong national leadership.
Production Area: 174.600 m2
Annual Production Capacity: 750 million units
GMP Certificates: Türkiye, Infarmed EU (Portugal), BDA EU (Bulgaria), Ukraine, Eurasia, Saudi Arabia, UAE, Uzbekistan, Canada, Bahrain, Philippines, Russia, Iraq, Peru, Jordan FDA, Libya, South Africa, Gulf Countries, Anvisa (Brasil)
Other Certificates: ISO 9001 Quality Management, ISO 27001 Information Security Management, ISO 14001 Environmental Management, ISO 45001 Occupational Health and Safety Management, ISO 50001 Energy Management
Number of Employees: 6.000